Kai Li

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Small Cell Lung Cancer

Top Venues

Cancer biology & medicine

Cancer medicine

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chao-Nan Qian, Bao-Hui Han, Kai Li
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial. Cancer biology & medicine (2024)
Yuan Gao, Yingfang Feng, Shaochuan Liu, Yan Zhang, Jing Wang, Tingting Qin, Peng Chen, Kai Li
Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib. Cancer medicine (2023)
Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang, Yan Yu, Jianhua Shi, Zhendong Chen, Xiaochun Zhang, Qisen Guo, Quan Liu, Huijuan Wu, Jian Fang, Yi Hu, Xiuwen Wang, Cuicui Han, Kai Li, Bao-Hui Han
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer biology & medicine (2021)
Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng, Kai Li
Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer. Cancer biology & medicine (2021)
Tingting Qin, Zhujun Liu, Jing Wang, Junling Xia, Shaochuan Liu, Yanan Jia, Hailin Liu, Kai Li
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer biology & medicine 17 (3) (2021)
Xiaoling Zhang, Yan Zhang, Yanan Jia, Tingting Qin, Cuicui Zhang, Yueya Li, Chengmou Huang, Zhujun Liu, Jing Wang, Kai Li
Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling. Cancer biology & medicine 17 (2) (2021)
Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Bao-Hui Han, Kai Li, Qiming Wang, Li Zhang, Zhehai Wang, Ying Cheng, Jianxing He, Yuan-Kai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhian Liu
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Thoracic cancer 12 (17) (2021)
Tingting Qin, Junling Xia, Shaochuan Liu, Jing Wang, Hailin Liu, Yan Zhang, Yanan Jia, Kai Li
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients. Thoracic cancer 11 (5) (2020)
Ying Cheng, Bao-Hui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Jianxing He, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Baolan Li, Jing Zhu
Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. Cancer medicine 9 (8) (2020)
Zhujun Liu, Jing Wang, Zhaoting Meng, Xinyue Wang, Cuicui Zhang, Tingting Qin, Jinliang Chen, Xiangli Jiang, Liuchun Wang, Li Lin, Xiaoling Zhang, Peng Chen, Chun Huang, Richeng Jiang, Kai Li
CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: Analysis on ALTER-0303 study. Cancer medicine (2018)
Tingting Qin, Dingzhi Huang, Zhujun Liu, Xiaoling Zhang, Yanan Jia, Cory J Xian, Kai Li
Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer. Cancer science 109 (8) (2018)